Molecular targeted therapies for BTC, such as trastuzumab, deruxtecan, pertuzumab, tucatinib and emtansine, which were initially developed for HER2-positive breast cancer, have been tested in phase II trials with favorable outcomes (Table 2) [68–71]. Here, ERBB2 is linked to breast carcinoma.